Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022
November 04 2022 - 6:30AM
Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, announced today that it
will release third quarter 2022 results and corporate update on
Tuesday, November 15, 2022. The Company will host a conference call
at 8:30 a.m. EST / 14:30 CET.
The conference call will be available via phone
and webcast. The live audio webcast of the call will be available
in the “Webcasts” section on the “Investors” page of the Affimed
website
at https://www.affimed.com/investors/webcasts-and-corporate-presentation/.
To access the call by phone, please use
link https://register.vevent.com/register/BI62ec6e16028b424eba578af8c49e4240,
and you will be provided with dial-in details and a pin number.
Note: To avoid delays, we encourage participants
to dial into the conference call 15 minutes ahead of the scheduled
start time.
A replay of the webcast will be accessible at
the same link for 30 days following the call.
About Affimed N.V.Affimed
(Nasdaq: AFMD) is a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer by actualizing the untapped potential of the innate immune
system. The Company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the Company’s
people, pipeline and partners, please visit: www.affimed.com.
Investor Relations ContactAlexander
FudukidisDirector, Head of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024